AU2020299705B2 - A substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator - Google Patents

A substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator

Info

Publication number
AU2020299705B2
AU2020299705B2 AU2020299705A AU2020299705A AU2020299705B2 AU 2020299705 B2 AU2020299705 B2 AU 2020299705B2 AU 2020299705 A AU2020299705 A AU 2020299705A AU 2020299705 A AU2020299705 A AU 2020299705A AU 2020299705 B2 AU2020299705 B2 AU 2020299705B2
Authority
AU
Australia
Prior art keywords
formula
compound
disease
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020299705A
Other languages
English (en)
Other versions
AU2020299705A1 (en
Inventor
Anne Valade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of AU2020299705A1 publication Critical patent/AU2020299705A1/en
Application granted granted Critical
Publication of AU2020299705B2 publication Critical patent/AU2020299705B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020299705A 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator Active AU2020299705B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183641 2019-07-01
EP19183641.0 2019-07-01
PCT/EP2020/068181 WO2021001286A1 (en) 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

Publications (2)

Publication Number Publication Date
AU2020299705A1 AU2020299705A1 (en) 2021-12-09
AU2020299705B2 true AU2020299705B2 (en) 2026-03-19

Family

ID=67137842

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020299705A Active AU2020299705B2 (en) 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator

Country Status (24)

Country Link
US (1) US12358890B2 (https=)
EP (1) EP3993795B1 (https=)
JP (1) JP7618597B2 (https=)
KR (1) KR102949226B1 (https=)
CN (1) CN114008032B (https=)
AR (1) AR119317A1 (https=)
AU (1) AU2020299705B2 (https=)
BR (1) BR112021022379A2 (https=)
CA (1) CA3139622A1 (https=)
CL (1) CL2021002949A1 (https=)
CO (1) CO2021017740A2 (https=)
EC (1) ECSP22007557A (https=)
IL (1) IL289317B2 (https=)
MA (1) MA56445A (https=)
MX (1) MX2021015872A (https=)
MY (1) MY210362A (https=)
PE (1) PE20220373A1 (https=)
PH (1) PH12021552819A1 (https=)
SA (1) SA521431274B1 (https=)
SG (1) SG11202112539XA (https=)
TW (1) TWI842923B (https=)
UA (1) UA130613C2 (https=)
WO (1) WO2021001286A1 (https=)
ZA (1) ZA202109194B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2976784T3 (es) 2020-10-07 2024-08-08 Lilly Co Eli Derivados de fenil-3,4-dihidroisoquinolin-2(1H)-il-etan-1-ona como moduladores alostéricos positivos del receptor de dopamina D1
EP4304577A1 (en) * 2021-03-09 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016055479A1 (en) * 2014-10-08 2016-04-14 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
WO2017178377A1 (en) * 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2679735A1 (en) 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
IN2014CN03234A (https=) 2011-11-03 2015-07-03 Merck Sharp & Dohme
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP7090099B2 (ja) * 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016055479A1 (en) * 2014-10-08 2016-04-14 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
WO2017178377A1 (en) * 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives

Also Published As

Publication number Publication date
CA3139622A1 (en) 2021-01-07
JP2022537994A (ja) 2022-08-31
IL289317B1 (en) 2025-05-01
EP3993795B1 (en) 2026-04-22
IL289317B2 (en) 2025-09-01
SG11202112539XA (en) 2021-12-30
IL289317A (en) 2022-02-01
ZA202109194B (en) 2023-11-29
TWI842923B (zh) 2024-05-21
MA56445A (fr) 2022-05-11
WO2021001286A1 (en) 2021-01-07
CN114008032B (zh) 2023-11-10
PH12021552819A1 (en) 2022-09-28
ECSP22007557A (es) 2022-02-25
AR119317A1 (es) 2021-12-09
SA521431274B1 (ar) 2024-01-09
CL2021002949A1 (es) 2022-07-15
JP7618597B2 (ja) 2025-01-21
KR102949226B1 (ko) 2026-04-06
US20220251064A1 (en) 2022-08-11
US12358890B2 (en) 2025-07-15
CO2021017740A2 (es) 2022-01-17
BR112021022379A2 (pt) 2022-03-08
PE20220373A1 (es) 2022-03-16
UA130613C2 (uk) 2026-04-01
TW202115009A (zh) 2021-04-16
CN114008032A (zh) 2022-02-01
AU2020299705A1 (en) 2021-12-09
KR20220029687A (ko) 2022-03-08
EP3993795A1 (en) 2022-05-11
MX2021015872A (es) 2022-02-03
MY210362A (en) 2025-09-13

Similar Documents

Publication Publication Date Title
AU2020299953B2 (en) A substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator
EP3442945B1 (en) Tetrahydroisoquinoline derivatives
AU2020299705B2 (en) A substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator
WO2022129303A1 (en) Dihydroisoquinolinyl derivatives
RU2824527C2 (ru) Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1
CA3202993A1 (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
RU2824581C2 (ru) Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1
HK40060812A (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
HK40060812B (zh) 作为d1正变构调节剂的取代的四氢异喹啉衍生物
HK40058931A (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
HK40058931B (zh) 作为d1正变构调节剂的取代的四氢异喹啉衍生物